Dalfampridine

AMPYRA

Potassium Channel Blocker

NADAC/unit $0.3859

No Shortage Tier 1: 20.1% PA Req: 83.0% 5 Manufacturers 5 ANDAs

Dalfampridine extended-release tablets are indicated as a treatment to improve walking in adult patients with multiple sclerosis (MS).

vs. brand AMPYRA: Generic saves up to 96% per unit

Covered Lives

Generic Manufacturers

ACCORD HEALTHCARE INCACTAVIS LABORATORIES FL INCALKEM LABORATORIES LTDAUROBINDO PHARMA LTDMERZ PHARMACEUTICALS LLCMICRO LABS LTD

Explore in the Ecosystem

rxsaver.aiCompare prices for Dalfampridine drfinder.aiFind doctors who prescribe Dalfampridine rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Dalfampridine

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.